Guide
Bacteriostatic water for injection is a pharmaceutical-grade diluent used to reconstitute lyophilized (freeze-dried) peptide powders into a liquid solution. It is distinct from plain sterile water in one critical respect: it contains a preservative that allows the vial to be used more than once. Understanding what bacteriostatic water is — and what it is not — is essential for anyone handling reconstituted peptides, whether in a research, compounding, or clinical context. This guide covers its composition, how it differs from sterile water, shelf life, storage requirements, regulatory status, and common misconceptions.
Bacteriostatic water for injection is sterile water that contains 0.9% benzyl alcohol as a bacteriostatic preservative. The term 'bacteriostatic' means the preservative inhibits the growth and reproduction of bacteria — it does not actively kill bacteria already present (that would be 'bactericidal'). The benzyl alcohol prevents bacterial contamination that could occur when a vial is punctured with a needle and entered multiple times. The product is manufactured under pharmaceutical-grade conditions and is regulated by the FDA as a drug product.
USP monograph defining Bacteriostatic Water for Injection as sterile water for injection containing 0.9% benzyl alcohol as a bacteriostatic preservative, intended for multi-dose use after initial entry.
FDA-approved drug label for Bacteriostatic Water for Injection (Hospira), containing 0.9% benzyl alcohol as a preservative, labeled for multi-dose use and not for neonatal use due to benzyl alcohol toxicity risk.
Sterile water for injection and bacteriostatic water for injection are both sterile and both intended for use as diluents, but they differ in one fundamental way: the presence of a preservative. Sterile water for injection contains no preservative. Once a vial of sterile water is opened or punctured, it must be used immediately and any remaining contents discarded — it is a single-use product. Bacteriostatic water, because it contains benzyl alcohol, can be re-entered multiple times within a limited window after the first puncture. This makes bacteriostatic water the standard diluent for multi-dose vials of reconstituted peptides, where the solution may be drawn from over days or weeks.
USP monograph defining Bacteriostatic Water for Injection as sterile water for injection containing 0.9% benzyl alcohol as a bacteriostatic preservative, intended for multi-dose use after initial entry.
FDA-approved drug label for Bacteriostatic Water for Injection (Hospira), containing 0.9% benzyl alcohol as a preservative, labeled for multi-dose use and not for neonatal use due to benzyl alcohol toxicity risk.
FDA-approved drug label for Sterile Water for Injection, a single-dose, preservative-free sterile water product intended for dilution only, with no bacteriostatic agent and therefore limited to single-use after opening.
Bacteriostatic water has two different shelf-life considerations: the unopened vial shelf life and the in-use (post-opening) shelf life. An unopened vial of bacteriostatic water typically has a manufacturer expiration date printed on the label — often 18 to 36 months from the date of manufacture when stored properly. Once the vial seal is broken (the rubber stopper is punctured with a needle), the in-use shelf life is typically 28 days. This 28-day window is consistent with CDC guidance on multi-dose vials and reflects the practical limit of the preservative's effectiveness against repeated environmental exposure.
CDC guidance on the safe handling of multi-dose vials, including the 28-day discard rule for opened multi-dose vials, storage temperature, and contamination risk reduction practices.
USP monograph defining Bacteriostatic Water for Injection as sterile water for injection containing 0.9% benzyl alcohol as a bacteriostatic preservative, intended for multi-dose use after initial entry.
Bacteriostatic water should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F) per USP guidelines. It should be kept away from direct sunlight, heat sources, and freezing temperatures. The vial should remain sealed with the original rubber stopper intact until first use. Once opened, the vial should be kept refrigerated if the reconstituted peptide product requires refrigeration, though the bacteriostatic water itself is generally stable at room temperature. Always check the specific storage requirements of the reconstituted peptide, as some peptides are temperature-sensitive and require refrigeration after reconstitution regardless of the diluent used.
USP monograph defining Bacteriostatic Water for Injection as sterile water for injection containing 0.9% benzyl alcohol as a bacteriostatic preservative, intended for multi-dose use after initial entry.
USP <797> establishes standards for sterile compounding including the use of bacteriostatic water for injection in multi-dose preparations, beyond-use dating, and storage requirements for reconstituted products.
Lyophilized peptides are supplied as a dry powder and must be reconstituted with a liquid diluent before use in research or clinical settings. Bacteriostatic water is the most commonly used diluent for this purpose because the preservative allows the reconstituted solution to be stored and drawn from over a period of time without rapid bacterial contamination. When a multi-dose vial of peptide powder is reconstituted with plain sterile water, each subsequent puncture of the stopper introduces bacteria that have no preservative to inhibit their growth. Bacteriostatic water's benzyl alcohol addresses this gap. USP <797>, which governs sterile compounding, recognizes bacteriostatic water for injection as an appropriate diluent for multi-dose compounded preparations.
USP <797> establishes standards for sterile compounding including the use of bacteriostatic water for injection in multi-dose preparations, beyond-use dating, and storage requirements for reconstituted products.
USP monograph defining Bacteriostatic Water for Injection as sterile water for injection containing 0.9% benzyl alcohol as a bacteriostatic preservative, intended for multi-dose use after initial entry.
Bacteriostatic water for injection is an FDA-regulated pharmaceutical product. It is manufactured under FDA oversight, has an approved drug label (e.g., the Hospira/Pfizer NDA), and is defined by a United States Pharmacopeia (USP) monograph that specifies its composition, sterility, and quality standards. It is not a dietary supplement, a cosmetic, or a research chemical — it is a recognized pharmaceutical product with established quality and safety standards. This distinguishes it from unregulated 'bacteriostatic water' that may be sold online without FDA registration, which may not meet USP monograph requirements for sterility, preservative concentration, or manufacturing quality.
FDA-approved drug label for Bacteriostatic Water for Injection (Hospira), containing 0.9% benzyl alcohol as a preservative, labeled for multi-dose use and not for neonatal use due to benzyl alcohol toxicity risk.
USP monograph defining Bacteriostatic Water for Injection as sterile water for injection containing 0.9% benzyl alcohol as a bacteriostatic preservative, intended for multi-dose use after initial entry.
FDA overview of the Drug Quality and Security Act (DQSA), which established sections 503A (traditional compounding pharmacies, state-regulated) and 503B (outsourcing facilities, FDA-registered, cGMP) of the FD&C Act, defining different regulatory requirements for each compounding category.
Several misconceptions about bacteriostatic water circulate in online peptide communities. These can lead to unsafe handling practices or incorrect assumptions about what the product does and does not do.
FDA-approved drug label for Bacteriostatic Water for Injection (Hospira), containing 0.9% benzyl alcohol as a preservative, labeled for multi-dose use and not for neonatal use due to benzyl alcohol toxicity risk.
CDC guidance on the safe handling of multi-dose vials, including the 28-day discard rule for opened multi-dose vials, storage temperature, and contamination risk reduction practices.
FDA safety notice warning that benzyl alcohol, the preservative in bacteriostatic water, can cause fatal 'gasping syndrome' in neonates and premature infants. Bacteriostatic water is contraindicated in newborns.
USP monograph defining Bacteriostatic Water for Injection as sterile water for injection containing 0.9% benzyl alcohol as a bacteriostatic preservative, intended for multi-dose use after initial entry.
While bacteriostatic water is a well-established pharmaceutical product, it carries specific safety considerations that are important to understand. The most significant is the contraindication in neonates: benzyl alcohol has been associated with fatal 'gasping syndrome' in premature infants and newborns. Bacteriostatic water for injection should never be used in neonatal preparations. Additionally, allergic reactions to benzyl alcohol, while rare, have been reported. Individuals with known benzyl alcohol sensitivity should use preservative-free sterile water for injection instead.
FDA safety notice warning that benzyl alcohol, the preservative in bacteriostatic water, can cause fatal 'gasping syndrome' in neonates and premature infants. Bacteriostatic water is contraindicated in newborns.
FDA-approved drug label for Bacteriostatic Water for Injection (Hospira), containing 0.9% benzyl alcohol as a preservative, labeled for multi-dose use and not for neonatal use due to benzyl alcohol toxicity risk.
Educational concentration calculator for lyophilized powder unit math — no dosing or administration guidance.
Browse source-backed peptide explainers by topic and regulatory status.
How people access peptides through research-use-only suppliers and licensed telehealth prescribing.
Full list of tracked FDA, peer-reviewed, and community sources.
Free report
Use the same checklist Peptide Report uses to evaluate COA documentation, supplier transparency, and analytical testing claims.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
This guide is informational. It does not recommend purchasing peptides from any supplier, provide medical advice, or evaluate whether any compound is appropriate for human use. Research-use-only products are not regulated as drugs, and COA documentation does not imply safety or efficacy.
Source records are stored in the repo and linked from each section.
USP monograph defining Bacteriostatic Water for Injection as sterile water for injection containing 0.9% benzyl alcohol as a bacteriostatic preservative, intended for multi-dose use after initial entry.
FDA-approved drug label for Bacteriostatic Water for Injection (Hospira), containing 0.9% benzyl alcohol as a preservative, labeled for multi-dose use and not for neonatal use due to benzyl alcohol toxicity risk.
FDA-approved drug label for Sterile Water for Injection, a single-dose, preservative-free sterile water product intended for dilution only, with no bacteriostatic agent and therefore limited to single-use after opening.
FDA safety notice warning that benzyl alcohol, the preservative in bacteriostatic water, can cause fatal 'gasping syndrome' in neonates and premature infants. Bacteriostatic water is contraindicated in newborns.
CDC guidance on the safe handling of multi-dose vials, including the 28-day discard rule for opened multi-dose vials, storage temperature, and contamination risk reduction practices.
USP <797> establishes standards for sterile compounding including the use of bacteriostatic water for injection in multi-dose preparations, beyond-use dating, and storage requirements for reconstituted products.
FDA overview of the Drug Quality and Security Act (DQSA), which established sections 503A (traditional compounding pharmacies, state-regulated) and 503B (outsourcing facilities, FDA-registered, cGMP) of the FD&C Act, defining different regulatory requirements for each compounding category.